Sun Pharma Advanced Research Co Current Share Price | Sun Pharma Advanced Research Co Stock Screener
SPARC
Pharmaceuticals
Sun Pharma Advanced Research Co Current Stock Price Today
Live Share Price NSE
₹193.92
▲
0.76 (0.39%)
Live Share Price BSE
₹194.05
▲
0.75 (0.39%)
As of September 18, 2026, the live Sun Pharma Advanced Research Co share price (NSE: SPARC) is ₹193.92 on NSE and ₹194.05 on BSE, up 0.39% from the previous close, with shares trading between ₹192.39 and ₹198.60 in today's trading session, and a 52-week range of ₹108.71–₹277.57.
Browse SPARC balance sheet details to support your investment research.
Use the Sun Pharma Advanced Research Co stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Sun Pharma Advanced Research Co Market Cap
₹6,360.52 Cr.
SPARC P/E Ratio (TTM)
4.03
Sun Pharma Advanced Research Co P/B Ratio
4.77
EPS (TTM)
₹47.86
Dividend Yield
-
Debt to Equity
0.74
SPARC 52 Week High
₹277.57
Sun Pharma Advanced Research Co 52 Week Low
₹108.71
Operating Margin
-85.00%
Profit Margin
-32.81%
SPARC Revenue (TTM)
₹64.00
EBITDA
₹-10.00
Net Income
₹-21.00
Total Assets
₹2,171.00
Total Equity
₹1,339.00
Sun Pharma Advanced Research Co Current Share Price Chart
Track the current Sun Pharma Advanced Research Co share price and stock price with an interactive chart. Analyse SPARC price trends, trading volume, historical performance, and volatility across different timeframes — the complete Sun Pharma Advanced Research Co stock quote in one place.
Sun Pharma Advanced Research Co Company Profile - Fundamental Screener
Screen Sun Pharma Advanced Research Co company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for SPARC shares.
Sun Pharma Advanced Research Company Ltd. (SPARC) is an India-based clinical-stage biopharmaceutical company focused on developing new drugs and delivery systems. It specializes in creating therapeutics in oncology, neurology, and immunology. SPARC's key projects include vodobatinib for chronic myelogenous leukemia and neurodegenerative diseases, an anti-MUC-1 antibody-drug conjugate for multiple cancers,...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Dilip S Shanghvi
ISIN
INE232I01014
Website
https://www.sparc.life
Sun Pharma Advanced Research Co Balance Sheet Screener
Screen SPARC balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Assets | ||||
| Total Assets | 2,171 | 336 | 515 | 830 |
| Current Assets | 1,862 | 26 | 269 | 455 |
| Fixed Assets | 85 | 99 | 108 | 106 |
| Liabilities | ||||
| Total Liabilities | 0 | 0 | 0 | 0 |
| Current Liabilities | 78 | 178 | 124 | 138 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||
| Total Equity | 1,339 | -217 | 126 | 513 |
| Share Capital | 33 | 33 | 33 | 33 |
| Reserves & Surplus | 1,306 | -249 | 93 | 480 |
Sun Pharma Advanced Research Co Income Statement Screener - Profit & Revenue Analysis
Screen Sun Pharma Advanced Research Co income statement and profit fundamentals.
Analyze SPARC quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Sun Pharma Advanced Research Co share price evaluation.
| Item | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 64 | 15 | 8 | 8 | 19 | 27 | 15 | 13 | 18 | 21 | 20 | 30 | 34 | 58 |
| Expenses | 74 | 80 | 77 | 74 | 62 | 80 | 89 | 116 | 110 | 122 | 117 | 113 | 126 | 137 |
| EBITDA | -10 | -65 | -69 | -66 | -43 | -53 | -74 | -103 | -92 | -101 | -96 | -83 | -92 | -79 |
| Operating Profit % | -85.00% | -506.00% | -817.00% | -836.00% | -540.00% | -196.00% | -494.00% | -800.00% | -555.00% | -639.00% | -740.00% | -432.00% | -427.00% | -188.00% |
| Depreciation | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Interest | 8 | 12 | 9 | 8 | 6 | 5 | 3 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -21 | 1,761 | -80 | -76 | -52 | -61 | -79 | -107 | -96 | -105 | -100 | -86 | -95 | -82 |
| Tax | 0 | 0 | 0 | 0 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | -21 | 1,761 | -80 | -76 | -52 | -60 | -80 | -107 | -96 | -106 | -100 | -86 | -95 | -82 |
| EPS | -0.64 | 54.27 | -2.48 | -2.34 | -1.60 | -1.84 | -2.45 | -3.31 | -2.96 | -3.26 | -3.07 | -2.66 | -2.94 | -2.55 |
Sun Pharma Advanced Research Co Cash Flow Screener - Liquidity Fundamentals
Screen SPARC cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2026-March | 2025-March | 2024-March | 2023-March |
|---|---|---|---|---|
| Operating Activities | -239 | -360 | -429 | -69 |
| Investing Activities | -23 | 158 | 392 | -548 |
| Financing Activities | 261 | 199 | 42 | 617 |
| Net Cash Flow | -1 | -3 | 5 | -1 |
Sun Pharma Advanced Research Co Shareholding Pattern Screener
See Sun Pharma Advanced Research Co shareholding pattern with promoter, FII, and DII holdings.
Check Sun Pharma Advanced Research Co promoter holding and ownership changes for SPARC on TickJournal.
| Item | 2026-Mar | 2026-May | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 65.67% | 65.67% | 65.67% | 65.67% | 65.67% | 65.67% | 65.67% | 65.67% |
| FII Holding | 2.04% | 2.47% | 3.90% | 1.45% | 1.47% | 1.76% | 2.04% | 3.23% |
| DII Holding | 0.88% | 0.10% | 0.09% | 1.13% | 0.97% | 1.05% | 0.78% | 0.82% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 16.81% | 19.13% | 18.57% | 18.99% | 19.15% | 18.94% | 19.20% | 16.11% |
| Other Holding | 14.60% | 12.63% | 11.76% | 12.76% | 12.73% | 12.59% | 12.30% | 14.17% |
| Shareholder Count | 140,625 | 137,538 | 141,957 | 142,864 | 140,724 | 136,997 | 144,810 | 102,743 |
Sun Pharma Advanced Research Co Share Dividend Screener - Share Yield Analysis
Check Sun Pharma Advanced Research Co dividend history with payout and yield data.
View Sun Pharma Advanced Research Co dividend details including ex-dates and amounts for SPARC stock.
Sun Pharma Advanced Research Co Stock Index Membership
See which indices include Sun Pharma Advanced Research Co stock.
Check SPARC index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE INDEX BSE HC
BSE INDEX BSE500
BSE INDEX MSL400
BSE INDEX SML250
BSE INDEX SMLCAP
NIFTY MICROCAP250
NIFTY TOTAL MKT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
Sun Pharma Advanced Research Co Market Events Screener - Corporate Actions
Get Sun Pharma Advanced Research Co corporate actions including splits, bonuses, and buybacks.
Check Sun Pharma Advanced Research Co stock events that may affect SPARC share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-08-10 | 2026-08-10 | Quarterly Result Announcement | NA | 3.22% |
| 2026-08-10 | 2026-08-10 | Annual General Meeting | NA | -11.08% |
| 2026-05-18 | 2026-05-18 | Quarterly Result Announcement | NA | -5.48% |
| 2026-02-09 | 2026-02-09 | Extraordinary General Meeting | NA | 2.66% |
| 2026-02-09 | 2026-02-09 | Quarterly Result Announcement | NA | 4.31% |
| 2025-11-10 | 2025-11-10 | Quarterly Result Announcement | NA | -2.70% |
| 2025-08-12 | 2025-08-12 | Annual General Meeting | NA | -9.43% |
| 2025-08-04 | 2025-08-04 | Quarterly Result Announcement | NA | -1.46% |
| 2025-05-19 | 2025-05-19 | Quarterly Result Announcement | NA | 14.10% |
| 2025-02-10 | 2025-02-10 | Quarterly Result Announcement | NA | 0.65% |
| 2024-11-04 | 2024-11-04 | Quarterly Result Announcement | NA | 4.07% |
| 2024-08-12 | 2024-08-12 | Annual General Meeting | NA | -12.92% |
Sun Pharma Advanced Research Co Competitors Screener - Peer Comparison
Screen SPARC competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 441,478 | 36.91 | 61,674 | 12.69% | 11,565 | 34.00 |
| Divis Laboratories | 247,470 | 85.36 | 11,067 | 13.95% | 2,568 | 63.65 |
| Torrent Pharmaceuticals | 188,872 | 86.95 | 13,886 | 20.34% | 2,138 | 52.16 |
| Zydus Life Science | 112,608 | 24.28 | 27,658 | 17.64% | 5,026 | 45.64 |
| Cipla | 110,352 | 33.22 | 29,045 | 2.24% | 3,870 | 35.27 |
| Laurus Labs | 106,298 | 95.94 | 6,868 | 22.01% | 890 | 68.28 |
| Dr Reddys Laboratories | 97,281 | 29.91 | 35,059 | 3.90% | 4,158 | 47.72 |
| Aurobindo Pharma | 96,652 | 25.88 | 34,145 | 5.56% | 3,503 | 57.04 |
| Lupin | 95,790 | 17.09 | 29,039 | 26.75% | 5,356 | 28.17 |
| Mankind Pharma | 94,163 | 44.87 | 14,636 | 14.85% | 1,938 | 37.57 |
Sun Pharma Advanced Research Co Company Announcements - News Screener
Screen SPARC latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-08-13 | Filing Of Application For Reclassification With Stock Exchanges | - |
| 2026-08-11 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-10 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-08-10 | Announcement under Regulation 30 (LODR)-Monitoring Agency Report | - |
| 2026-08-10 | Unaudited Financial Results For The Quarter Ended June 30 2026 | - |
| 2026-08-10 | Board Meeting Outcome for Outcome Of The Board Meeting | - |
| 2026-08-03 | Board Meeting Intimation for Approval Of Unaudited Standalone And Consolidated Financial Results For The Quarter Ended June 30 2026 | - |
| 2026-07-27 | Intimation For Receipt Of Requests For Reclassification Of Shareholder Category | - |
| 2026-07-17 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-07-16 | Business Responsibility and Sustainability Reporting (BRSR) | - |
| 2026-07-16 | Notice Of 21St Annual General Meeting To Be Held On August 10 2026 Along With The Annual Report For FY 26 | - |
| 2026-07-16 | Reg. 34 (1) Annual Report. | - |
| 2026-07-13 | Announcement under Regulation 30 (LODR)-Change in Directorate | - |
| 2026-07-09 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-07-06 | Intimation Regarding 21St Annual General Meeting Of The Company | - |
| 2026-07-06 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-06-26 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-06-25 | Termination Of License Agreement With CMS Bridging DMCC | - |
| 2026-06-24 | Closure of Trading Window | - |
| 2026-05-25 | Statutory Auditors Certificate In Terms Of Regulation 169(5) Of SEBI ICDRA Regulations 2018 | - |